Loading...
•
Mar 31, 2025
CSP Q3 2025 Earnings Report
CSP reported Q2 2025 results with lower revenue and profitability compared to the prior year, impacted by the absence of a large prior-year deal.
Key Takeaways
CSPi posted $13.1 million in revenue and a $0.01 loss per share for Q2 2025. Gross margin decreased to 32% as the prior year included a significant multi-million-dollar product deal. The company highlighted continued traction for AZT PROTECT and maintained a strong cash position with no long-term debt.
Revenue for Q2 2025 was $13.1 million, down from $13.7 million in Q2 2024.
Gross profit dropped to $4.2 million due to lower high-margin deals.
GAAP EPS was a loss of $0.01, compared to income of $0.16 last year.
Cash and cash equivalents remained strong at $29.5 million with no long-term debt.
Revenue by Segment
Forward Guidance
CSPi expressed confidence in the long-term growth of AZT PROTECT and expects large deal opportunities to materialize over the next 18–24 months.
Positive Outlook
- Signed new AZT PROTECT customers in Q2, including in South Africa.
- Renewed 12-month support contract with a global pharma firm.
- Maintained strong cash position and no long-term debt.
- Repurchased 23,800 shares in Q2 2025.
- Growing brand recognition and traction with key resellers and manufacturers.
Challenges Ahead
- Revenue and margins declined due to lack of large prior-year deal.
- Net loss of $0.01 per share compared to $0.16 EPS last year.
- Gross margin fell to 32%, down from 47% year-over-year.
- Operating income turned negative at $(994,000).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...